12:51 PM
 | 
Mar 02, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Prometic discontinues Phase II of PBI-4050 to treat cystic fibrosis related diabetes

Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) said it will discontinue a Phase II trial of PBI-4050 to treat cystic fibrosis related diabetes due to slow patient enrollment. The company said most CF patients were ineligible for the trial as they...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >